Program
donanemab
Also written as “Donanemab”, “LY3002813” and “LY3002813-IV”.
Its studies are mostly in Alzheimer Disease · Cognitive Dysfunction, led by Eli Lilly.
Furthest: phase 4, since Sep 18, 202614 company-led studies, 7 open or runningNext primary completion: Nov 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 147 open or running | phase 4since Sep 18, 2026 | Apr 18, 2013 | Nov 2027phase 3 · NCT05026866 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 18, 2013First study: phase 1 study in Alzheimer DiseaseFirst studyNCT01837641 · 63 enrolled · United States, Japan
- Dec 4, 2015Phase 1 study in Alzheimer DiseaseNCT02624778 · 61 enrolled · United States, Japan
- Dec 5, 2017Phase 2 study in Alzheimer DiseaseNCT03367403 · 272 enrolled · United States, Canada
- Jun 17, 2020Phase 3 study in Alzheimer DiseaseNCT04437511 · 1,736 enrolled · United States, Australia, Canada and more
- Nov 9, 2020Phase 2 study in Alzheimer DiseaseNCT04640077 · 95 enrolled · United States, Canada
- Aug 27, 2021Phase 3 study in Alzheimer DiseaseNCT05026866 · 2,996 enrolled · United States, Japan, Puerto Rico
- Oct 26, 2021Phase 3 study in Cognitive DysfunctionNCT05108922 · 148 enrolled · United States
- Aug 18, 2022Phase 3 study in Alzheimer DiseaseNCT05508789 · 1,500 enrolled · Argentina, Australia, China and more
- Sep 6, 2022Phase 1 study in HealthyNCT05533411 · 36 enrolled · China
- Oct 3, 2022Phase 1 study in HealthyNCT05567159 · 42 enrolled · United States
- Apr 30, 2026Phase 3 study in Alzheimer DiseaseNCT07571161 · 140 planned · China
- May 11, 2026Phase 2 study in Cognitive DysfunctionNCT07589595 · 350 planned · United States, Japan, South Korea and more
- May 15, 2026Phase 3 study in Alzheimer DiseaseNCT07602582 · 550 planned · United States, Japan, Puerto Rico
- Sep 18, 2026Phase 4 study in Alzheimer DiseaseNCT07838155 · 50 planned · India
Ahead
- Nov 2027Primary completion: phase 3 study in Alzheimer DiseaseNCT05026866
- May 2028Primary completion: phase 3 study in Alzheimer DiseaseNCT05508789
- Aug 2028Primary completion: phase 2 study in Cognitive DysfunctionNCT07589595
- Sep 2029Primary completion: phase 3 study in Alzheimer DiseaseNCT07602582
TargetBeta
APP →read by rule
“Amyloid-beta A4 protein disrupting agent”ChEMBL 37, by rule
Other programs on APP
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07838155Alzheimer Disease · India | 4 | Not yet recruiting | Sep 2030 | 50 |
| NCT07602582Alzheimer Disease · United States, Japan, Puerto Rico | 3 | Recruiting | Sep 2029 | 550 |
| NCT07589595Cognitive Dysfunction · United States, Japan, South Korea and more | 2 | Recruiting | Aug 2028 | 350 |
| NCT07571161Alzheimer Disease · China | 3 | Recruiting | Apr 2030 | 140 |
| NCT05567159Healthy · United States | 1 | Completed | Jul 14, 2023 | 42 |
| NCT05533411Healthy · China | 1 | Completed | Jan 5, 2023 | 36 |
| NCT05508789Alzheimer Disease · Argentina, Australia, China and more | 3 | Active, not recruiting | May 2028 | 1,500 |
| NCT05108922Cognitive Dysfunction · United States | 3 | Completed | Sep 9, 2022 | 148 |
| NCT05026866Alzheimer Disease · United States, Japan, Puerto Rico | 3 | Active, not recruiting | Nov 2027 | 2,996 |
| NCT04640077Alzheimer Disease · United States, Canada | 2 | Completed | Feb 27, 2024 | 95 |
| NCT04437511Alzheimer Disease · United States, Australia, Canada and more | 3 | Active, not recruiting | Apr 14, 2023 | 1,736 |
| NCT03367403Alzheimer Disease · United States, Canada | 2 | Completed | Dec 4, 2020 | 272 |
| NCT02624778Alzheimer Disease · United States, Japan | 1 | Completed | Aug 28, 2019 | 61 |
| NCT01837641Alzheimer Disease · United States, Japan | 1 | Completed | Aug 24, 2016 | 63 |
How it is read
Names in the registry
- “Donanemab”, 11 entries
- “donanemab”, 1 entry
- “LY3002813”, 1 entry
- “LY3002813-IV”, 1 entry
- “LY3002813-SC”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 10 studies
- Cognitive Dysfunction, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.